Immune Pharmaceuticals Inc buy klostergang
Start price
07.04.15
/
50%
€30.46
Target price
07.10.15
€60.00
Performance (%)
-32.76%
End price
07.10.15
€20.48
Summary
This prediction ended on 07.10.15 with a price of €20.48. Massive losses of -32.76% were the result for the BUY prediction by klostergang. klostergang has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Immune Pharmaceuticals Inc | - | - | - | - |
| iShares Core DAX® | 4.015% | 2.971% | 16.492% | 19.144% |
| iShares Nasdaq 100 | 2.755% | 0.503% | 40.029% | 50.636% |
| iShares Nikkei 225® | -0.826% | -5.057% | 14.566% | 2.379% |
| iShares S&P 500 | 2.330% | 0.720% | 30.194% | 44.181% |
Comments by klostergang for this prediction
In the thread Immune Pharmaceuticals Inc diskutieren
Immune Pharma developping target therapeutics for the treatment of inflammatory diseases and cance
Immune Pharmaceuticals recently completed long-term financing that should fund operations for at least the next 18 months. The company’s lead asset, bertilimumab, is currently being tested in Phase 2 clinical trials for bullous pemphigoid and ulcerative colitis. Immune recently in-licensed a topical nano-formulation of cyclosporine A and plans to develop it as a treatment for moderate psoriaisis and atopic dermatitis. Topline data from the company’s Phase 2 clinical study in bullous pemphigoid should be available before the end of 2015, representing a potential inflection point for the company.
(Laufzeit überschritten)